"All disease begins in the gut." - Hippocrates
Until recently, there has been little insight into the root cause of metabolic disease and, as a result, advancements to address the resulting conditions have been incremental at best – addressing only symptoms, with little impact on patient outcomes. At Fractyl, we are applying new scientific insights in intestinal biology to advance treatments and potential cures for metabolic diseases.
Our product pipeline leverages our proprietary procedural therapy, which is designed to rejuvenate the lining of the duodenum to improve patient health, and initially targets patients with metabolic conditions resulting from insulin resistance, including type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS).
The intestinal lining (duodenal mucosa) is our body’s largest hormone-producing (“endocrine”) organ, the largest nervous system outside of the brain, an important line of defense against infection, and host to a complex microbiome.
Our research has demonstrated that insulin resistance is caused by an overgrowth (hyperplasia) of the duodenal lining that results from years of diets high in fats and sugar. This hyperplasia leads to changes in the amount of key hormones produced and key nutrients absorbed in this section of the gut. These changes affect both insulin production by the pancreas and the body’s responsiveness to that insulin. Because of these hormonal signals, when the mucosa becomes hyperplastic, patients become predisposed to insulin resistance and metabolic disease.
To treat and hopefully reverse metabolic diseases, we have developed Revita™ DMR (duodenal mucosal resurfacing), a minimally invasive, outpatient procedural therapy designed to rejuvenate the lining of the duodenum.
We have received a CE Mark to commercialize Revita DMR in Europe based on our clinical work, and global, follow-on clinical trials are advancing in T2D, NASH and PCOS. In addition, we are exploring the use of our Revita DMR technology coupled with cell and gene therapy to fully restore patient health.
Our scientific insights in intestinal biology have led to discovery efforts beyond Revita DMR, including products in the pipeline targeting weight loss and intestinal cell + gene therapy. Contact Fractyl for more information about our pipeline.
The intestinal lining (duodenal mucosa) is our body’s largest hormone-producing (“endocrine”) organ, the largest nervous system outside of the brain, an important line of defense against infection, and host to a complex microbiome.